Covidien Release: Clinical Data for DURABILITY II Study Presented at ISET 2012

MIAMI--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that one-year results on the use of its EverFlex™ stent for superficial femoral artery stenting were presented here during the International Symposium on Endovascular Therapy (ISET) Conference.
MORE ON THIS TOPIC